Gevaert P, Omachi TA, Corren J, et al. - Researchers tested the effectiveness and safety of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 trials (POLYP 1, POLYP 2). Adults with CRSwNP with inadequate response to intranasal corticosteroids have been randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. According to results, patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) showed severe CRSwNP and substantial quality-of-life impairment evidenced by mean Nasal Polyp Score > 6 and Sino-Nasal Outcome Test-22 of ∼60. Omalizumab significantly improved, and was well tolerated, endoscopic, clinical and patient-reported outcomes in severe CRSwNP with inadequate response to intranasal corticosteroids. The adverse events between groups were similar.